O

Ollin Biosciences

HealthUnited States

Ollin Biosciences is developing treatments for eye diseases, specifically targeting conditions like diabetic macular edema and wet age-related macular degeneration. The company has raised $330 million in Series B funding to support its upcoming Phase 3 trial, making it one of the largest funding rounds for a biotech company in recent years.

$330M · Series BVisit website ↗

🏆 Featured in Datapile’s Q2 2026 USA Funding Report

Read the Q2 2026 USA report →
Add this badge to your site
<a href="https://datapile.co/reports/q2-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q2 2026 USA Funding Report</a>

Funding history

  1. $330MSeries B2026-06-24
    Source: news.google.com

Investors in Ollin Biosciences

Backers from this company's tracked funding rounds.

  • TCGX
  • ARCH Venture Partners

More Health companies

Recently funded startups in the same category.

Related on Datapile